鼠神经生长因子对糖尿病性视神经病变的疗效分析

Efficacy of mouse nerve growth factor in treating diabetic optic neuropathy

目的:探讨鼠神经生长因子(mouse nerve growth factor,M-NGF)治疗糖尿病性视神经病变(DON)的疗效及安全性。方法:糖尿病性视神经病变患者67例115眼,根据是否需要激光视网膜光凝治疗分为两组,每组随机分为常规治疗组和M-NGF治疗组,均给予常规治疗,M-NGF治疗组加用M-NGF,疗程3wk。治疗后随访2mo,比较各组患者治疗后视力、视野恢复情况,并观察M-NGF治疗的安全性。结果:在不需要激光视网膜光凝组,常规治疗和M-NGF治疗的总有效率分别为71.4%和94.7%,后者总有效率高于前者(P<0.05);在需要激光视网膜光凝组,常规治疗和M-NGF治疗的总有效率分别为73.0%和93.3%,后者总有效率高于前者(P<0.05);在激光组和非激光组,治疗效果无明显统计学差异(P>0.05)。除个别患者注射部位出现局部疼痛、红肿硬结外,未见其它不良反应。结论:M-NGF治疗DON安全、有效,值得临床推广应用。

AIM： To investigate the efficacy and safety of the mouse nerve growth factor（M-NGF）in treating diabetic optic neuropathy（DON）.METHODS： All 67 cases（115 eyes）with DON were randomly divided into two groups according to the need of photocoagulation or not, and each group was randomly divided into normal treatment group and M-NGF treatment group. Patients in normal treatment group were treated by conventional way and those in M-NGF treatment group were treated with M-NGF plus conventional treatment for 3 weeks. Two months later, the vision and visual field of different groups were inspected and the safety was evaluated. RESULTS： The effective rate was 71.4% in normal treatment group and 94.7% in M-NGF treatment group（P〈0.05）in non-photocoagulation group, and 73.0% in normal treatment group and 93.3% in M-NGF treatment group（P〈0.05）in photocoagulation group. The general effective rate of later was higher than the former（P〈0.05）, while the treatment effect had no significant statistical difference（P〉0.05）. Apart from local injection pain and swelling scleroma in several patients, other side effects were not found.CONCLUSION： M-NGF is an effective and safe way to treat DON, which is worth widely applying in clinical practice.